MX2009013003A - Derivados de piperidina-amida. - Google Patents

Derivados de piperidina-amida.

Info

Publication number
MX2009013003A
MX2009013003A MX2009013003A MX2009013003A MX2009013003A MX 2009013003 A MX2009013003 A MX 2009013003A MX 2009013003 A MX2009013003 A MX 2009013003A MX 2009013003 A MX2009013003 A MX 2009013003A MX 2009013003 A MX2009013003 A MX 2009013003A
Authority
MX
Mexico
Prior art keywords
sup
amide derivatives
piperidine
cpt1
medicaments
Prior art date
Application number
MX2009013003A
Other languages
English (en)
Inventor
Patrizio Mattei
Odile Chomienne
Mirjana Andjelkovic
Simona M Ceccarelli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009013003A publication Critical patent/MX2009013003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a nuevos derivados de piperidinaamida de la fórmula (I) (ver fórmula I) en la que R1, R2, X e Y tienen los significados definidos en la descripción y en las reivindicaciones, así como a sus sales y ésteres fisiológicamente aceptables. Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos.
MX2009013003A 2007-06-01 2008-05-22 Derivados de piperidina-amida. MX2009013003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109458 2007-06-01
PCT/EP2008/056309 WO2008145596A1 (en) 2007-06-01 2008-05-22 Piperidine-amide derivatives

Publications (1)

Publication Number Publication Date
MX2009013003A true MX2009013003A (es) 2010-01-20

Family

ID=39645621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013003A MX2009013003A (es) 2007-06-01 2008-05-22 Derivados de piperidina-amida.

Country Status (17)

Country Link
US (1) US8039487B2 (es)
EP (1) EP2155738B1 (es)
JP (1) JP5220848B2 (es)
KR (1) KR101140520B1 (es)
CN (1) CN101679404B (es)
AR (1) AR066759A1 (es)
AT (1) ATE518857T1 (es)
AU (1) AU2008257693B2 (es)
BR (1) BRPI0811978A2 (es)
CA (1) CA2689383C (es)
CL (1) CL2008001552A1 (es)
ES (1) ES2369315T3 (es)
IL (1) IL202159A (es)
MX (1) MX2009013003A (es)
PE (1) PE20090320A1 (es)
TW (1) TW200901997A (es)
WO (1) WO2008145596A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848908B (zh) * 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2015031710A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
AU2022269825A1 (en) * 2021-05-04 2023-11-09 2N Pharma Aps Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases
US20240293424A1 (en) * 2021-07-12 2024-09-05 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165519A1 (en) * 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
CA2608837C (en) * 2005-06-06 2011-08-02 F. Hoffmann-La Roche Ag Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors
WO2007031429A1 (en) * 2005-09-15 2007-03-22 F. Hoffmann-La Roche Ag Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
CN101321525B (zh) 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
MX2010011917A (es) * 2008-05-05 2010-11-26 Merck Patent Gmbh Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1.
DE102008029734A1 (de) * 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate

Also Published As

Publication number Publication date
AU2008257693A1 (en) 2008-12-04
KR20100017976A (ko) 2010-02-16
EP2155738B1 (en) 2011-08-03
AR066759A1 (es) 2009-09-09
CA2689383A1 (en) 2008-12-04
WO2008145596A1 (en) 2008-12-04
JP5220848B2 (ja) 2013-06-26
IL202159A (en) 2013-07-31
EP2155738A1 (en) 2010-02-24
PE20090320A1 (es) 2009-03-19
CA2689383C (en) 2013-10-08
CN101679404A (zh) 2010-03-24
ATE518857T1 (de) 2011-08-15
IL202159A0 (en) 2010-06-16
KR101140520B1 (ko) 2012-04-30
US20080300279A1 (en) 2008-12-04
AU2008257693B2 (en) 2011-01-27
BRPI0811978A2 (pt) 2014-11-18
ES2369315T3 (es) 2011-11-29
JP2010529001A (ja) 2010-08-26
TW200901997A (en) 2009-01-16
US8039487B2 (en) 2011-10-18
CL2008001552A1 (es) 2009-05-22
CN101679404B (zh) 2012-06-13

Similar Documents

Publication Publication Date Title
TW200833324A (en) Sulfonamide derivatives
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
TW200626558A (en) Indazolone derivatives
TW200738655A (en) Novel bicyclic sulfonamide derivatives
MX2010003224A (es) Derivados de biaril sulfonamida.
MX2009010218A (es) Derivados de aza-piridopirimidinona.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
IN2012DN03337A (es)
MX2007004699A (es) Derivados de indol y bencimidazol.
MX2010005824A (es) Derivados de aminotiazol.
MY138941A (en) Aryl-pyridine derivatives
TW200745032A (en) Novel heterobicyclic derivatives
TW200738241A (en) Pyridazine derivatives
TW200612958A (en) Substituted imidazole derivatives
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2009010567A (es) Derivados de imidazolidinona.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MX2007013203A (es) Nuevas aminas ciclicas.
PH12013500942A1 (en) Triazolopyridine compounds
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2010001742A (es) Nuevos derivados de piperazina-amida.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten

Legal Events

Date Code Title Description
FG Grant or registration